These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 28800141)

  • 21. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
    Einolf HJ; Zhou J; Won C; Wang L; Rebello S
    Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
    Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
    Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
    Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
    J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
    Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L; Neuwirth R; Egorin M; Chatta G
    Clin Ther; 2009; 31 Pt 2():2444-58. PubMed ID: 20110052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of drug-drug interactions of pemigatinib in healthy participants.
    Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1887-1897. PubMed ID: 34282472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.
    Yang J; Pradhan RS; Rosen LS; Graham AM; Holen KD; Xiong H
    J Clin Pharm Ther; 2014 Dec; 39(6):680-4. PubMed ID: 25047139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
    Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
    Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
    Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
    Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
    Gupta N; Diderichsen PM; Hanley MJ; Berg D; van de Velde H; Harvey RD; Venkatakrishnan K
    Clin Pharmacokinet; 2017 Nov; 56(11):1355-1368. PubMed ID: 28290121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.
    Liu X; Zhang Y; Chen Q; Zhan Y; Wang Q; Hu C; Yu C; Guo Z; Chen X; Zhong D
    J Clin Pharmacol; 2018 Mar; 58(3):347-356. PubMed ID: 28967981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
    Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
    CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lurasidone drug-drug interaction studies: a comprehensive review.
    Chiu YY; Ereshefsky L; Preskorn SH; Poola N; Loebel A
    Drug Metabol Drug Interact; 2014; 29(3):191-202. PubMed ID: 24825095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.